Parkinson's disease: Madopar is indicated for the treatment of Parkinson's disease with the exception of drug-induced Parkinsonism.
Madopar dispersible is a formulation which is suitable for patients with dysphagia (difficulties in swallowing) or who require a formulation with a more rapid onset of action, e.g. patients suffering from early morning and afternoon akinesia, or who exhibit 'delayed on' or 'wearing off' phenomenon.
Madopar HBS is indicated for patients presenting with all types of fluctuations (i.e. 'peak dose dyskinesia' and 'end of dose deterioration' - such as nocturnal immobility).